Keyword: Johnson & Johnson
The Takeda-Shire deal passes investors; Sun suffers from a long list of allegations; J&J and Legend update CAR-T data.
An industrywide probe of pharma's charitable contributions has spawned multimillion-dollar settlements, and Actelion is the latest to deal with the feds.
Just a year after approval, AZ’s Calquence is giving Imbruvica a run for its money in MCL. But the British drugmaker doesn’t want to stop there.
As officials scramble to contain an Ebola outbreak in the Democratic Republic of Congo, the WHO is worried that Merck's vaccine stockpile won't last.
Johnson & Johnson and AbbVie’s Imbruvica already competes in previously untreated CLL. But the partners are looking to own it.
J&J's Darzalex made multiple myeloma history in May with an FDA nod in newly diagnosed patients. And now, it’s looking for a repeat.
Based in Oxford and slated to open in 2022, the center will focus on creating rapid, cost-effective ways of developing and manufacturing vaccines.
J&J’s clot-busting Xarelto may not have hit the primary goal in its latest trial, but the company still believes it can win a new approval down the line.
An appeals court rejected a motion by J&J to issue an injunction against Zytiga generics, potentially opening the market as a patent case plays out.
After losses and mistrials this year in its talc defense, Johnson & Johnson has scored a second straight win in a mesothelioma case in California.